Nuredis Inc, [1501 - 1501] Adams Dr, Menlo Park, CA 94025, US

Trellis Bioscience, located in Menlo Park, CA, is a biotechnology company specializing in the development of native human monoclonal antibodies (mAbs) for the treatment of infectious diseases and cancer. With their proprietary CellSpot platform, Trellis has built a robust pipeline of products targeting serious infections, including prosthetic joint infections, as well as prominent viruses such as human cytomegalovirus, respiratory syncytial virus, and influenza. Their lead product, TRL1068, has shown promising results in reducing biofilm burden in prosthetic joint infections, with a high rate of bacterial biofilm removal after only 7 days of treatment. As the fastest-growing class of drugs in the pharmaceutical industry, mAbs have become increasingly cost-effective for a wide range of diseases, and Trellis is at the forefront of leveraging this technology. Their innovative approach has led to the discovery of native human mAbs against immune checkpoint modulators and tumor-associated antigens, providing new insights into immune surveillance against cancer. With a focus on safety, efficacy, and improving patient outcomes, Trellis Bioscience is dedicated to advancing the field of biotechnology and making a significant impact in the fight against infectious diseases and cancer.Generated from the website

DNA 2.0

Vortex Biosciences Inc

Daniel 2:28

Dice Molecules Corporation